Souhaitez-vous accéder aux communiqués récents ?

Nyxol has Potential to be a New Eye Drop Treatment Option for Presbyopia Top-Line VEGA-1 Data Expected by End of Q2 2021 FARMINGTON HILLS, Mich., May 12, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma,...

Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication ...

Oral Administration of APX3330 Reduced Neovascularization in a Pre-Clinical Mouse Model of Laser-Induced Choroidal Neovascularization New Data from Physiological-Based Pharmacokinetic (PBPK) Model...

APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy Top Line Data from ZETA-1 Expected by Early 2022 ...

FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed...

Nyxol Meets Its Primary and Multiple Secondary Endpoints Including Statistically Significant Efficacy Returning Subjects More Rapidly to Normal Pupil Size Across a Breadth of Dilating Agents and Iris...

FARMINGTON HILLS, Mich., March 10, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...

Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design Topline Results for Phase 3 MIRA-2 Trial Expected in March 2021 ...

HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9thOppenheimer Healthcare Conference at 9:20 am ET on March 18th FARMINGTON HILLS, Mich., March 04, 2021 (GLOBE...

Nyxol and Low-Dose (0.4%) Pilocarpine Combination to Target Improvement in Near Vision in a Presbyopic Population Top Line Data from VEGA-1 Expected End of 2Q21 FARMINGTON HILLS, Mich.,...